Product Name: ERK3 (191-200) pT194+pY197+pS199
Product Number: PE-04ATQ80
| Size: | 200 µg | Price: | 43.00 | |
| 1 mg | $US | 86.00 |
Peptide Name: ERK3 (191-200) pT194+pY197+pS199
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The presentation as a dimer increases the potential activity. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Phosphorylation of T194, Y197 and S199 is predicted to inhibit phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: (GLV-pT-KW-pY-R-pS-P-βA-Cys)2
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The presentation as a dimer increases the potential activity. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Phosphorylation of T194, Y197 and S199 is predicted to inhibit phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: (GLV-pT-KW-pY-R-pS-P-βA-Cys)2
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated, dimer
Peptide Molecular Mass Calculated: 3237.4 Da
Peptide Purity Percent after Synthesis and Purification: >50
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: Not stable
Peptide Molecular Mass Calculated: 3237.4 Da
Peptide Purity Percent after Synthesis and Purification: >50
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: Not stable
Scientific Background: ERK3 (MAPK6) is a protein-serine/threonine kinase of the CMGC group and MAPK family. ERK3 is highly expressed in the skeletal muscle and the brain. It is located in nucleus and has been shown to be activating in fibroblasts with serum or phorbol esters treatments. Phosphorylation at S189 increases its phosphotransferase activity. Overexpression of ERK3 in fibroblasts inhibits S-phase entry. It may act as a negative regulator of cell proliferation. It is downregulated in different tumour types. However regulation and function of ERK3 remains to be fully elucidated. It phosphorylates MAP2.
© Kinexus Bioinformatics Corporation 2017